India, Oct. 23 -- Biocon Ltd announced that its subsidiary, Biocon Biologics Ltd, has received approval from Health Canada for its biosimilar products Yesintek (ustekinumab injection) and Yesintek IV (ustekinumab for injection, solution for intravenous infusion).
The Notice of Compliance (NOC) granted by Health Canada allows the use of these medications for treating chronic autoimmune conditions.
Both products are biosimilars to Stelara and Stelara IV, developed by Janssen, used for the treatment of various autoimmune diseases.
Published by HT Digital Content Services with permission from Dion Global Solutions Limited....